This is a preview of subscription content, log in via an institution to check access.
Notes
The study was funded by Vifor Pharma Ltd.
Reference
Widen J, et al. Cost-Effectiveness Analysis of Patiromer in Combination with Renin-Angiotensin-Aldosterone System Inhibitors for Chronic Kidney Disease in Sweden. PharmacoEconomics : 2 Apr 2020. Available from: URL: https://doi.org/10.1007/s40273-020-00902-w
Rights and permissions
About this article
Cite this article
Patiromer cost-effective hyperkalaemia treatment in CKD in Sweden. PharmacoEcon Outcomes News 851, 34 (2020). https://doi.org/10.1007/s40274-020-6757-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-6757-x